-
From GPO to national procurement, analysis of changes in the market structure of large varieties!
Time of Update: 2021-06-10
Valaciclovir Hydrochloride Tablets In October 2016, Shanghai announced the results of the second batch of GPO winning bids, showing that there are two bidding companies for valacyclovir hydrochloride tablets, namely Shanghai Shangyao Xinyi and Chengdu Beite.
-
Smeglutide has been approved by the FDA for weight loss indications!
Time of Update: 2021-06-10
The Phase IIIa study included 4 trials, enrolling a total of approximately 4,500 overweight or obese adult patients, of which:The STEP 1 study (adjuvant life>The results showed that after 68 weeks of treatment with smeglutide, the intention-to-treat patients lost 16.
-
American virologist: The possibility that the new crown will come from the laboratory is almost non-existent
Time of Update: 2021-06-10
Peter Dasak, Chairman of the American Ecological Health Alliance: During the 15 years of working with Wuhan Institute of Virology, everything I learned is what is happening in the virus laboratory.
-
Hongri Pharmaceuticals Sagrexate Hydrochloride Tablets Obtained Drug Registration Approval
Time of Update: 2021-06-08
On June 2, Hongri Pharmaceutical issued an announcement stating that it had recently received a drug registration approval document for sargresil hydrochloride tablets issued by the State Food and Drug Administration.
has been approved to market sargresil hydrochloride tablets in China.
-
Zhendong Pharmaceutical Terminates Asset Replacement and Related Party Transactions
Time of Update: 2021-06-08
Zhendong Pharmaceutical announced on the evening of June 1 to terminate asset swaps and related-party transactions.
(Zhendong Pharmaceutical Announcement)Zhendong Pharmaceutical announced on the evening of June 1 to terminate asset swaps and related-party transactions.
Zhendong Pharmaceutical originally planned to divest its long-term loss-making asset Ante Pharmaceutical.
-
Shanghai Kaibao Tanreqing Capsules Newly Added Indications Application Approved for Clinical
Time of Update: 2021-06-08
In the original "clearing heat, resolving phlegm, detoxification.
Used for wind-warming lung-heat disease, which belongs to the syndrome of wind-heat attacking the lung, symptomatic fever, nausea, cough, sputum, or sore throat, runny nose, dry mouth, etc.
-
Health Commission: 24 new confirmed cases and 15 local cases
Time of Update: 2021-06-08
As of 24:00 on June 2, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are 364 confirmed cases (including 7 severe cases), 86,170 cured and discharged cases, and 4,636 deaths.
-
A Brief Discussion on the Pharmaceutical Research of Bayberry Flavonoids
Time of Update: 2021-06-08
Myrica flavonoids have a good anti-inflammatory effect on DSS-induced ulcerative colitis in mice, which can reduce NO, myeloperoxidase (MPO) and MDA, and at the same time increase the activities of SOD and GSH-Px. Anti-inflammatoryAnti-inflammatoryInflammation is a defense-oriented response when various damage factors act on the body.
-
BMJ: SGLT-2 inhibitor/GLP-1 receptor agonist treatment of type 2 diabetes
Time of Update: 2021-06-08
Recently, The British Medical Journal (The BMJ) published international clinical practice guidelines, recommending SGLT-2 inhibitors or GLP-1 receptor agonists for adult type 2 diabetes, focusing on patients with different heart and kidney risks, and evaluating The benefits and harms of these two types of drugs combined with conventional diagnosis and treatment (life>The guidelines are jointly formulated by clinical and methodological experts from more than ten countries around the world.
-
Liaoning will carry out special rectification actions for commercial advertisements for "magic doctors" and "magic medicines"
Time of Update: 2021-06-08
(Finish) Medical Network News, June 2 In order to severely crack down on the chaos of "magic medicine" and "magic medicine" advertisements in accordance with the law, the Liaoning Provincial Market Supervision Bureau, the Provincial Health Commission, the Provincial Radio, Film and Television Bureau, and the Provincial Food and Drug Administration will start from June 1 to November On the 15th, jointly organized a special rectification action on commercial advertisements for "magic doctor" and "magic medicine".
-
Frustrated again!
Time of Update: 2021-06-08
The study of venglustat in patients with autosomal dominant polycystic kidney disease is an attempt to explore new biological effects of glycosphingolipids in addition to the known role in lysosomal storage disease (LSD).
-
The medical insurance payment standard policy may be introduced!
Time of Update: 2021-06-08
In April 2016, the General Office of the State Council's "Key Tasks for Deepening the Reform of the Medical and Health System in 2016" required: "Develop basic medical insurance drug payment standards in accordance with relevant national policies.
-
Which ADC pipeline layout is strong? Look at the first Sankyo
Time of Update: 2021-06-08
Dato-DXd is an antibody-conjugated drug (ADC) targeting TROP2 for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) with unchanged genome.
-
The State Food and Drug Administration issued a notice on the suspension of production and rectification of Guangzhou Aixinda Electronics Co., Ltd.
Time of Update: 2021-06-08
Recently, the State Food and Drug Administration organized an unannounced inspection of Guangzhou Aixinda Electronics Co. , Ltd. , and the inspection found that the company's quality management system
-
The hospital medication review is here!
Time of Update: 2021-06-08
At the end of 2020, the National Health Commission issued the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)", according to the current actual situation of oncology drugs in hospitals, implementing drug classification management, emphasizing the evidence-based use of drugs, and emphasizing the standard formulation of drug treatment plans.
-
Janssen Amivantamab was approved to be marketed as the world's first bispecific antibody for the treatment of NSCLC
Time of Update: 2021-06-08
The drug was approved by the US FDA on May 21, 2021 for the treatment of non-small cell lung cancer with EGFR mutations [1].
2~3% of patients with non-small cell lung cancer have EGFR exon 20 insertion mutations.
-
Huadong Medicine: Subsidiary obtains an exclusive license agreement for the product under research SCO-094
Time of Update: 2021-06-08
Sino-US East China will make a down payment of US$4 million to SCOHIA, up to a development and registration milestone of US$11 million, and a sales milestone of US$13 million.
-
Zhejiang released the "14th Five-Year" Chinese Medicine Development Plan, invests 56 billion yuan
Time of Update: 2021-06-08
According to Xie Xiaobo, deputy director of the Zhejiang Provincial Development and Reform Commission and first-level inspector, the "Plan" adheres to the integration of Chinese medicine undertakings and industries, and is based on the positioning of the "five resources" of Chinese medicine (unique health resources, economic resources with huge potential) , Science and technology resources with original advantages, excellent cultural resources and important ecological resources), committed to improving the integration, integrity and systemicity of the development of Chinese medicine.
-
Guess the dose and break the medicine?
Time of Update: 2021-06-08
" Zhao Zhigang said that children of different ages vary greatly, and the dosage of drugs cannot simply be halved by parents' feelings.
" Zhao Zhigang said that children of different ages vary greatly, and the dosage of drugs cannot simply be halved by parents' feelings.
-
Simcere and Boao Evergrande International Hospital cooperate to use Trilaciclib for the first clinical treatment of Chinese patients
Time of Update: 2021-06-08
and Boao Evergrande International Hospital introduced the drug, approved by the Hainan Provincial Drug Administration, for the first time in Boao Evergrande International Hospital for the clinical treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
